Autoimmune
Diseases:
Systemic Lupus Erythematosus (SLE) |
| This page was written
by Shelley Ensz, and has
not yet been medically edited. See Disclaimer. |
|
|
|
| Antibodies
in Lupus |
| Antiphospholipid antibody syndrome and autoimmune diseases. Evidence is growing that antiphospholipid antibodies may have a pathogenic role in pulmonary hypertension and accelerated atherosclerosis of autoimmune diseases. (PubMed) Hematol Oncol Clin North Am. 2008 Feb; 22(1):53-65. (Also see: Antibodies, PH,and Cardiac) |
| New biomarkers for lupus found. Mishra said microRNAs are a class of small chains of ribonucleic acid that have important regulatory functions in the body, particularly in suppressing genes. "We are the first to show that these micro-RNAs are a problem in human lupus." EurekAlert! 11/10/06. |
| Quantitation
of autoantibodies in systemic autoimmune diseases: clinically
useful? Treatment based on changes in levels of the respective
autoantibodies only seems at present not justified, in view
of the toxicity of currently available immunosuppressive
regimens. (Sage Journals OnLine) Lupus, Vol. 15, No. 7, 397-402 (2006) (Also see: Antibodies) |
| Yale
scientists identify structure for RNA quality control. A
report by Yale scientists in the journal Cell sheds new light
on how the protein Ro, a major autoantigen in patients with
autoimmune disease, recognizes misfolded RNAs, creating a
RNA quality control system for cells. Medical News Today.
06/02/05. (Also see: Sjogren's
Syndrome) |
| Autoantibody
explosion in systemic lupus erythematosus: More than 100
different antibodies found in SLE patients. SLE is the
autoimmune disease with the largest number of detectable
autoantibodies. Their production could be antigen-driven,
the result of polyclonal B cell activation, impaired apoptotic
pathways, or the outcome of idiotypic network dysregulation. PubMed.
Semin Arthritis Rheum. 2004 Oct;34(2):501-37. |
| The
immune response to cell death in SLE. Since circulating
DNA in the form of immune complexes can play a role in lupus
pathogenesis, these findings suggest that the generation
and clearance of dead cells are important events that may
underlie autoimmunity in this disease and may be targeted
for therapy. PubMed. Autoimmun Rev. 2004 Nov;3(7-8):500-4. |
| Anti-Lactoferrin |
| Anti-lactoferrin
antibodies in patients with connective tissue diseases. Patients
with connective tissue diseases are known to develop multiple
auto-antibodies; anti-lactoferrin antibodies mainly of IgG1
isotype can also be found in patients with rheumatoid arthritis
and more often in patients with systemic lupus erythematosus. PubMed.
Folia Med (Plovdiv). 2003;45(4):25-30. (Also see: Rheumatoid
Arthritis) |
| C Reactive Protein
(Anti-CRP) |
| Autoantibodies Against C-Reactive Protein: Clinical Associations in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome. We observed that the presence of these antibodies was associated with lupus nephritis and with clinical features of the APS in patients with lupus and non-lupus patients. J Rheumatol 2006;33:1980-6. (Also see: APS and Antibodies) |
| Serum
levels of autoantibodies against monomeric C-reactive protein
are correlated with disease activity in systemic lupus erythematosus.
This indicates that anti-CRP antibodies might have biological
functions of pathogenetic interest in SLE. Arthritis Res
Ther 2004, 6:R87-R94. |
| Serum
levels of autoantibodies against monomeric C-reactive protein
are correlated with disease activity in systemic lupus erythematosus.
This indicates that anti-CRP antibodies might have biological
functions of pathogenetic interest in SLE. Arthritis Res
Ther 2004, 6:R87-R94. |
